

|                      |   |                      |  |                      |   |
|----------------------|---|----------------------|--|----------------------|---|
| <b>Day 1</b>         | <b>Policy and Epidemiology</b>  |                      |  |                      |   |
| <b>07.00</b>         | <b>Registration</b>   |                      |  |                      |   |
| <b>08.30 - 12.30</b> | <b>Opening Ceremony and Session A: How do we Work Together to Achieve HCV Elimination Among People who Inject Drugs?</b><br>Room: Sala I + II<br>Chairs: Rui Tato Marinho, Hospital Santa Maria; Medical School of Lisbon; Portuguese Society of Gastroenterology, Portugal; Jeffrey Lazarus, ISGlobal; Hospital Clínic; University of Barcelona, Spain; Ricardo Baptista Leite, Member of Parliament, Portuguese National Parliament, Portugal; Luís Mendão, GAT, Portugal |                      |  |                      |   |
| 08.0 - 08.45         | Welcome to the Symposium  |                      |  |                      |   |
| 08.45 - 09.30        | <b>Policy Opening and Report from Policy Day</b><br>Ricardo Baptista Leite, Member of Parliament, Portuguese National Parliament, Portugal  |                      |  |                      |   |
| 09.30 - 09.35        | <b>Opening from European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)</b><br>Alexis Goosdeel, European Monitoring Centre for Drugs and Drug Addiction, (EMCDDA), Portugal  |                      |  |                      |   |
| 09.35 - 09.45        | <b>Community Opening and Report from Community Summit</b><br>Eberhard Schatz, Correlation Network, Amsterdam; Magda Ferreira, GAT, Portugal   |                      |  |                      |   |
| 09.45 - 09.55        | <b>Awards</b>   |                      |  |                      |   |
| 09.55 - 10.00        | <b>IJDP</b><br>Tim Rhodes, London School of Hygiene and Tropical Medicine and Editor-in-Chief for the International Journal of Drug Policy, United Kingdom  |                      |  |                      |   |
| <b>10.00 - 10.30</b> | <b>Coffee Break and Poster Viewing</b>  |                      |  |                      |   |
| <b>10.30 - 12.30</b> | <b>Session A continued</b><br>Room: Sala I + II<br>Chairs: Judy Chang, Daniel Simões & Margaret Hellard   |                      |  |                      |   |
| 10.30 - 10.50        | <b>Successes and Challenges of Drug Policy in Portugal: Decriminalization is not Enough</b><br>João Goulão, General-Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD), Portugal   |                      |  |                      |   |
| 10.50 - 11.10        | <b>What will it Take to Achieve the HCV Elimination Goals Among People who Inject Drugs?</b><br>Annette Verster, World Health Organization, Switzerland   |                      |  |                      |   |
| 11.10 - 11.20        | <b>Questions &amp; Discussion</b>   |                      |  |                      |   |
| 11.20 - 11.30        | <b>Is it All They Said it Would Be? Drug Users Experience of Portuguese Decriminalisation</b><br>Rui Miguel Coimbra Morais, Consumers Associated Survive Organised (CASO)   |                      |  |                      |   |
| 11.30 - 11.40        | <b>Rewriting the Policy Narrative: Hepatitis C and a Right to Health</b><br>James Dunne, Australian Injecting & Illicit Drug Users League (AIVL), Vienna  |                      |  |                      |   |
| 11.40 - 12.00        | <b>Panel Discussion: Humanising Efforts to Reach People who Inject Drugs: Decriminalisation, Rights and Health</b><br>Panelists: Rui Miguel Coimbra Morais, Consumers Associated Survive Organised (CASO), Portugal; James Dunne, Australian Injecting & Illicit Drug Users League (AIVL), Vienna; Jude Byrne, Australian Injecting & Illicit Drug Users League (AIVL), Australia; João Goulão, General-Directorate for Intervention on Addictive Behaviours and            |                      |  |                      |   |
| 12.00 - 12.15        | <b>Sexualised Drug Use and Co-Occurring High Risk Behaviours Among Gay and Bisexual Men Living with HIV/Hepatitis C Co-infection in Melbourne, Australia</b><br>Brendan Harney, Alfred Health & Burnet Institute, Australia   |                      |  |                      |   |
| 12.15 - 12.30        | <b>Opiate Agonist Therapy and Prevention of HCV Transmission Among People who Inject Drugs: The Importance of Clinically-Indicated and Patient-Perceived Dosage Adequacy</b><br>Andrea Adelina Arteni, Université De Montréal, Canada   |                      |  |                      |   |
| <b>12.30 - 14.00</b> | <b>Lunch and Poster Viewing</b>   |                      |  |                      |   |
| <b>12.45 - 13.45</b> | <b>Lunch Symposium: Shaping Tomorrow Together: Insights from Experience</b><br>Room: Sala I + II  |                      |  |                      |   |
| <b>14.00 - 15.15</b> | <b>Session B: Epidemiology of HCV Infection</b><br>Room: Sala XII + XIII<br>Chairs: Jennifer Havens & Vivian Hope   | <b>14.00 - 15.15</b> | <b>Session C: Efforts to Enhance HCV Diagnosis and Testing</b><br>Room: Sala II<br>Chairs: Jude Byrne & Ryan Westergaard   | <b>14.00 - 15.15</b> | <b>Session D: Models of Care for HCV Infection</b><br>Room: Sala I<br>Chairs: Mojca Matičič & Filipe Calinas  |
| 14.00 - 14.15        | <b>Estimating the Number of People who Inject Drugs in Athens, Greece: Implications for the Burden of Hepatitis C Infection and the Coverage of Harm Reduction Programs</b><br>Sotirios Roussos, University Of Athens, Greece   | 14.00 - 14.15        | <b>Client and Staff Perspectives on Point-of-Care Hepatitis C Testing for People Attending Needle Syringe Programs</b><br>Ned Latham, Burnet Institute, Australia  | 14.00 - 14.15        | <b>Community Outreach Events – Engaging the Disengaged</b><br>Julie Holeksa, Vancouver Infectious Diseases Centre, Canada   |
| 14.15 - 14.30        | <b>Increased Risk of Hepatitis-C Virus and Skin and Soft Tissue Infection Among People Who Inject Novel Psychoactive Substances</b><br>Andrew McAuley, Glasgow Caledonian University, United Kingdom  | 14.15 - 14.30        | <b>Factors Associated with HCV Testing Among People who Inject Drugs in an Urban Setting in Vietnam</b><br>Giang Le, Hanoi Medical University, Vietnam   | 14.15 - 14.30        | <b>The Kombi Clinic Driving Out Hep C in South East Queensland Disenfranchised Communities</b><br>Joss O'Loan, Kombi Clinic, Australia  |
| 14.30 - 14.45        | <b>Combined Coverage of Harm Reduction Interventions and Rates of Primary and Recurrent HCV Infection in a Community-Based Cohort of People Who Inject Drugs</b><br>Nanor Minoyan, CRCHUM / Université De Montréal, Canada  | 14.30 - 14.45        | <b>Hepcatt (Hepatitis C Assessment To Treatment Trial) in Primary Care: A Cluster RCT of Whether a Complex Intervention Based on Risk Prediction Algorithm Tool and Education Can Increase Testing and Diagnosis of HCV in Primary Care</b><br>Matthew Hickman, Population Health Sciences, Bristol Medical School, United Kingdom | 14.30 - 14.45        | <b>Hepatitis C Screening and Linkage to Care at Four New York City Syringe Exchange Programs</b><br>Nirah Johnson, NYC Department Of Health And Mental Hygiene, United States                         |
| 14.45 - 14.50        | <b>Exposing the Need for Viral Hepatitis C Services for People who Inject Drugs in South Africa: Findings from a Three-City Cross Sectional Survey</b><br>Andrew Scheibe, TB HIV Care, South Africa   | 14.45 - 14.50        | <b>Linking Hepatitis C Infection People who Inject Drugs to Treatment and Care, South Africa</b><br>Angela McBride, Out Well-being, Harmless Project, South Africa   | 14.45 - 14.50        | <b>An Onsite Primary Care Based Approach Allows Rapid Reduction of Hepatitis C Prevalence in Prison. A Case Study From Canberra, Australia</b><br>Michael Levy, ACT Justice Health Service, Australia |

|               |   |               |   |               |   |
|---------------|---|---------------|---|---------------|---|
| 14.50 - 14.55 | <b>Increase in HCV Prevalence Among People who Inject Drugs in Ukraine</b><br>Tetiana Saliuk, Alliance For Public Health, Ukraine   | 14.50 - 14.55 | <b>High Prevalence of Current and Past Hepatitis C Virus Infections Among New Injectors Found in a Cross-Sectional Study in Germany, 2011-2014: Missed Opportunities for Counselling and Testing</b><br>Julia Enkelmann, Robert Koch Institute, Germany   | 14.50 - 14.55 | <b>The Road to Hepatitis C Elimination: A Change in Care Pathway Increases Access to Hepatitis C Treatment for People on Opiate Substitution Therapy</b><br>Brian Stephens, NHS Tayside, United Kingdom |
| 14.55 - 15.00 | <b>Factors Associated with Hepatitis C in HIV Positive Men who Have Sex with Men</b><br>Pablo Ryan, Infanta Leonor Hospital, Spain  | 14.55 - 15.00 | <b>The National Stigma Indicator Project: Key Findings and Lessons Regarding People Living with HCV and People who Inject Drugs</b><br>Carla Treloar, University of New South Wales, Australia  | 14.55 - 15.00 | <b>Implementation of Routine HIV/HCV Screening and Linkage to Care in the Idea Exchange; Miami, FL</b><br>Tyler Bartholomew, University of Miami, United States   |
| 15.00 - 15.05 | <b>Correlations Between Injecting Frequency and Housing Stability Trajectories Evolving Concomitantly Over One Year: Results from a Cohort Study of People who Inject Drugs in Montréal, Canada</b><br>Emmanuel Fortier, CHUM Research Centre, Canada | 15.00 - 15.05 | <b>Despite High Risk Behaviors, Including Chemsex, Barriers Exist for HCV Testing in MSM Throughout India</b><br>Brianna Norton, Montefiore Medical Center, United States   | 15.00 - 15.05 | <b>A Community-Based Model of Peer-Led Anonymous Rapid Hepatitis C (HCV) Testing for People who Inject Drugs (PWIDs) in Mauritius</b><br>Arnaud Nicolas Patrick Manbode, PILS, Mauritius                |
| 15.05 - 15.10 | <b>Housing Stability and Hepatitis C Infection for Young Adults who Inject Drugs:</b><br>Meghan Morris, University Of California, San Francisco, United States  | 15.05 - 15.10 | <b>People who Inject Drugs have Inequitable Chance to be HCV Tested</b><br>Iuliia Novak, ICF, Alliance for Public Health, Ukraine   | 15.05 - 15.10 | <b>A Responsive Model of Care Utilizing a Collaborative Nurse Practitioner and Peer Based Model of Care</b><br>Leanne Myers, Peer Based Harm Reduction WA, Australia                                    |
| 15.10 - 15.15 | <b>Attenuated Protective Effect of Opioid Agonist Therapy on Hepatitis C Incidence Among Females</b><br>Kimberly Page, University Of New Mexico, United States  | 15.10 - 15.15 | <b>Hepatitis C Testing, Treatment Uptake and Sustained Virologic Response Among Gay and Bisexual Men with Hepatitis C and HIV Co-Infection in Melbourne, Australia</b><br>Alisa Pedrana, Burnet Institute, Australia  | 15.10 - 15.15 | <b>Health Prevention Delegate: Visiting General Practitioners and Pharmacists in the Pyrénées Atlantiques Area (France)</b><br>Cecilia Maitre, Resapsad, France   |
| 15.15 - 16.15 | <b>Coffee Break &amp; Poster Tour</b>   |               |   |               |   |
| 16.15 - 17.45 | <b>Session E: Epidemiology and Public Health</b><br><b>Room: Sala I</b><br><b>Chairs: Sarah Larney &amp; Jennifer Havens</b>  | 16.15 - 17.30 | <b>Session F: Integration of HCV, Other Co-Infections and Harm Reduction Services (CHAFAEA Sponsored Session)</b><br><b>Room: Sala XII + XIII</b><br><b>Chairs: Jean Luc Sion &amp; Jeffrey Lazarus</b>   | 16.15 - 17.30 | <b>Session G: Monitoring HCV elimination among PWID (EMCDDA sponsored session)</b><br><b>Room: Sala II</b><br><b>Chairs: Jane Mounteny &amp; Antons Mozalevskis</b>                                     |
| 16.15 - 16.35 | <b>Epidemiology of HCV Infection Among People who Inject Drugs: Where do we Really Need to Focus Our Efforts to Eliminate HCV Globally?</b><br>Matthew Hickman, University of Bristol, United Kingdom   | 16.15 - 16.20 | <b>What Does the EU Mean by "Integrated" Infectious Disease Programmes and what Policy Developments have there Been to Further this Agenda?</b><br>Jean Luc Sion, DG SANTE, Portugal  | 16.15 - 16.30 | <b>Monitoring the Elimination of HCV as a Public Health Threat Among People who Inject Drugs in the EU</b><br>Thomas Seyler, EMCDDA, Portugal   |
|               |   | 16.20 - 16.25 | <b>Integration of HCV, Other Co-Infections and Harm Reduction Services for People Who Inject Drugs in Portugal</b><br>João Goulão, General-Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD), Portugal  |               |   |
| 16.35 - 16.55 | <b>Will HCV Reinfection Compromise Our Elimination Efforts?</b><br>Gregory Dore, Kirby Institute, University of New South Wales, Australia  | 16.25 - 16.35 | <b>How do EU Agencies take an Integrated Approach to Hepatitis C Control</b><br>Dagmar Hedrich, European Monitoring Centre for Drugs and Drug Addiction, (EMCDDA), Portugal   | 16.30 - 16.45 | <b>Model Projections of the Impact of HCV Treatment on Chronic HCV in European Settings</b><br>Hannah Fraser, University of Bristol, United Kingdom   |
| 16.55 - 17.15 | <b>Women Who Inject Drugs</b><br>Alena Asaeva, Eurasian Network of People who use Drugs (ENPUD), Russia   | 16.35 - 16.45 | <b>Best Practice Model from a Czech Republic Prison</b><br>Viktor Mravčík, National Monitoring Centre for Drugs and Addiction, Czech Republic   | 16.45 - 17.00 | <b>HCV Elimination in Dutch People who use Drugs? The 5 Steps of the National Hepatitis Plan</b><br>Esther Croes, Trimbos Instituut, Belgium  |
| 17.15 - 17.45 | <b>Questions &amp; Discussion</b>   | 16.45 - 17.00 | <b>Transitioning Specialist HCV Services into the Community</b><br>John (Jack) Jack Lambert, Hep-CARE, United Kingdom; Alistair Story, E-DETECT, United Kingdom   | 17.00 - 17.15 | <b>Towards HCV Elimination in People who Inject Drugs in Slovenia: How to Monitor a Real-Life Situation?</b><br>Moica Maticic, University of Ljubljana, Ukraine   |
|               |   | 17.00 - 17.45 | <b>What Does Integration of Services for People who Inject Drugs Mean in Terms of Testing and Providing Treatment? How Does the Health Systems Need to Change to Better Integrate and can it? Can we Eliminate Hepatitis C Among People who Inject Drugs on Opioid Substitution Therapy in the Near Future?</b><br>Panellists: Jeffrey Lazarus, HA-REACT, Spain; John (Jack) Lambert, Hep-Care, INTEGRATE, United Kingdom; Alistair Story, E-DETECT TB, United Kingdom, Raquel Duarte, Porto Integrated PWID Centre, Portugal; Viktor Mravčík, National Monitoring Centre for Drugs and Addiction, Czech Republic | 17.15 - 17.20 | <b>Progress and Challenges in Monitoring Elimination Among People who Inject Drugs</b><br>Ruth Zimmermann, Robert Koch Institute Berlin, Germany  |
| 17.45 - 19.00 | <b>Welcome Reception &amp; Poster Viewing</b>   |               |   |               |   |

|                      |   |               |   |               |   |
|----------------------|---|---------------|---|---------------|---|
| <b>Day 2</b>         | <b>HCV Diagnosis, Linkage to Care and Treatment</b>   |               |   |               |   |
| <b>07.30</b>         | <b>Registration</b>   |               |   |               |   |
| <b>08.00 - 08.45</b> | <b>Breakfast Symposium: A Personalised Approach to HCV Treatment: It's not just About the Virus</b><br>Room: Sala I + II  |               |   |               |   |
| <b>09.00 - 10.45</b> | <b>Session H: Enhancing the HCV Care Cascade</b><br>Room: Sala I + II<br>Chairs: Anne Øvrehus and Joseph Doyle  |               |   |               |   |
| 09:00 - 09:20        | Point-of-care Testing and Diagnostics for HCV Infection: Have we Reached a Single-visit Diagnosis?<br>Karine Lacombe, Sorbonne-Universités, Inserm - APHP, France   |               |   |               |   |
| 09:20 - 09:40        | Strategies to Foster Task-shifting and Broaden Models of HCV Prevention and Care<br>John Dillon, University of Dundee, United Kingdom   |               |   |               |   |
| 09:40 - 10:00        | Strategies to Facilitate Linkage to Care for People Who Inject Drugs in Low and Middle Income Countries<br>Shruti Mehta, John Hopkins Bloomberg School of Public Health, United States  |               |   |               |   |
| 10:00 - 10:15        | Questions & Discussion  |               |   |               |   |
| 10:15 - 10:30        | Rural Risk Environment For Hepatitis C Among Young Adults Who Use Opioids In Appalachian Kentucky<br>David Cloud, Emory University, Rollins School Of Public Health, United States  |               |   |               |   |
| 10:30 - 10:45        | Cost-Effectiveness Analysis of Testing Strategies for Diagnosing Hepatitis C Virus Infection in People Who Inject Drugs in Resource-Constrained Countries<br>Léa Duchesne, Inserm, France   |               |   |               |   |
| <b>10.45 - 11.15</b> | <b>Coffee Break and Poster Viewing</b>  |               |   |               |   |
| <b>11.15 - 12.15</b> | <b>Session I: Workshops</b>   |               |   |               |   |
|                      | Is it Cirrhosis? Is it Cancer? A Practical Guide<br>Room: Sala XIII   | 11.15 - 12.15 | Meaningful Patient And Public Involvement In HCV Research: A Focus On Peer Researchers<br>Room: Sala XII  |               |   |
|                      | Rui Tato Marinho, Hospital Santa Maria; Medical School of Lisbon; Portuguese Society of Gastroenterology, Portugal  |               | Emma Hamilton, Scottish Drugs Forum, United Kingdom   |               |   |
| <b>11.15 - 12.15</b> | <b>Session J: Epidemiology, Modelling and Cost-Effectiveness</b><br>Room: Sala II<br>Chairs: Vana Sypsa & Natasha Martin  | 11.15 - 12.15 | <b>Session K: Addressing Gaps to Improve HCV Treatment Access</b><br>Room: Sala I<br>Chairs: Tim Rhodes & Tessa Windelinckx   |               |   |
| 11.15 - 11.30        | The Cost-Effectiveness of Undertaking HCV Treatment in Needle and Syringe Programmes in Tayside, Scotland<br>Zoe Ward, University Of Bristol, United Kingdom  | 11.15 - 11.30 | Do National HCV Policies in the EU Address Treatment and Care for People Who Inject Drugs?<br>Stine Neilsen, Freelance, Spain   |               |   |
| 11.30 - 11.45        | Modelling the Impact of Prevention and Treatment Interventions on HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs in Nairobi<br>Jack Stone, University Of Bristol, United Kingdom  | 11.30 - 11.45 | Barriers and Facilitators of Hepatitis C (HCV) Treatment Initiation Among People Who Inject Drugs in the Era of New Direct Acting Antivirals<br>Iuliia Makarenko, McGill University, Canada   |               |   |
| 11.45 - 12.00        | Cost-Effectiveness of Scaling-Up Syringe Service Provision Among People Who Inject Drugs In Perry County, Kentucky<br>Hannah Fraser, University Of Bristol, United Kingdom  | 11.45 - 12.00 | W3 Framework: Understanding the Role And Quality of Peer Led Programs by People Who Inject Drugs in a National Hepatitis C Response<br>Graham Brown, Australian Research Centre In Sex, Health And Society, La Trobe University, Australia  |               |   |
| 12.00 - 12.05        | Estimation of the Number of People who Inject Drugs and Live With HIV and Viral Hepatitis Co-Infection in Ukraine<br>Kostyantyn Dumchev, Ukrainian Institute on Public Health Policy, Ukraine   | 12.00 - 12.05 | Knowledge Around Direct Acting Antiviral Therapies and Willingness to Undergo HCV Treatment Among Rural Appalachian Opioid Users<br>Jennifer Havens, University Of Kentucky College Of Medicine, United States  |               |   |
| 12.05 - 12.10        | The Results of HIV and HCV Prevention Program Among People Who Inject Drugs in Ukraine<br>Tetiana Mykhalchuk, Alliance For Public Health, Ukraine   | 12.05 - 12.10 | Attitude of Staff Regarding Integrated Hepatitis C Treatment at Eight Harm Reduction Centers in Georgia<br>Lasha Gulbiani, Health Research Union, Georgia   |               |   |
| 12.10 - 12.15        | A Cost-Effective Strategy to Reach the WHO Hepatitis C Virus (HCV) Elimination Target in Men Who Have Sex With Men in the UK : A 90% Decrease in Hepatitis C Incidence By 2030<br>Peter Vickerman, University Of Bristol, United Kingdom                                | 12.10 - 12.15 | Integrating Hepatitis C Care for At-Risk Groups: Findings from a Multi-Centre Observational Study in Primary and Community Care<br>Eithne Nic An Ríogh, University College Dublin, Ireland  |               |   |
| <b>12.15 - 13.45</b> | <b>Lunch and Poster Viewing</b>   |               |   |               |   |
| <b>12.30 - 13.30</b> | <b>Lunch Symposium: Striving for HCV Elimination – High-Risk Populations, High Reward?</b><br>Room: Sala I + II   |               |   |               |   |
| <b>13.45 - 15.00</b> | <b>Session L: Enhancing the HCV Care Cascade</b><br>Room: Sala XII + XIII<br>Chairs: Amy Nunn & Behzad Hajarizadeh  | 13.45 - 15.00 | <b>Session M: Strategies to Improve HCV Treatment Outcomes</b><br>Room: Sala I<br>Chairs: Nina Weis & Håvard Midgard  | 13.45 - 15.00 | <b>Session N: Models of Care for HCV Infection (Sponsored by IAS)</b><br>Room: Sala II<br>Chairs: Stéphanie Dominguez & Jorge Mera  |
| 13.45 - 14.00        | Conceptualising Access in the DAA Era: Applying the Candidacy Framework to Inform Research and Practice in HCV Care for People Who Use Drugs<br>Stine Høj, Centre de Recherche du CHUM, Canada  | 13.45 - 14.00 | Preliminary Analysis of the Superdot-C Study: a Cluster Randomised Controlled Trial of Pharmacy Led Versus Conventional Treatment for HCV Positive Patients Receiving Daily Opioid Substitution Therapy Within NHS Scotland<br>Andrew Radley, National Health Service Tayside, United Kingdom     | 13.45 - 14.00 | A Multi-Sectoral Model to Support Hepatitis C Testing and Treatment Access Among People Who Inject Drugs in Hanoi, Vietnam<br>Thuy Ma Thu, Medecins Du Monde - Vietnam Mission, Vietnam                   |
| 14.00 - 14.15        | Hepatitis C Virus (HCV) Testing, Liver Disease Assessment and Direct-Acting Antiviral (DAA) Treatment Uptake and Outcomes in a Homeless Service in Sydney, Australia: the Liverlife Study<br>Sahar Bajis, The Kirby Institute, University Of New South Wales, Australia | 14.00 - 14.15 | The Treatment as Prevention Approach Results in an Early and Marked Reduction in Prevalence of Hepatitis C Viremia Among People With Recent Injection Drug Use. Results from the Treatment as Prevention (TRAP HEPC) Program in Iceland<br>Valgerdur Runarsdottir, SAA Addiction Clinics, Iceland | 14.00 - 14.15 | Daily Dosing of Direct Acting Antivirals (DAA) from a Public Opioid Substitution Treatment (OST) Program for Marginalised Clients in Kings Cross, Sydney<br>Phillip Read, Kirketon Road Centre, Australia |

|   |  |                      |   |               |  |
|---|--|----------------------|---|---------------|--|
| 14.15 - 14.30                                       | <b>Straight to the Point – Lessons from the Rapid-EC Study: a Point-Of-Care Hepatitis C Testing Pilot in Needle and Syringe Programs Targeted to People Who Inject Drugs in Australia</b><br>Alisa Pedrana, Burnet Institute, Australia  | 14.15 - 14.30        | <b>Engaging People Who Inject Drugs in Community Based Treatment and Care Using a Nurse-Led, Social Network Model</b><br>Sally Von Bibra, The Burnet Institute, Australia   | 14.15 - 14.30 | <b>Indigenous Led Hepatitis C Treatment Model to Achieve Elimination in Big River First Nation</b><br>Stuart Skinner, University of Saskatchewan, Canada & Charlene Gardiner, Big River First Nation, Canada                 |
| 14.30 - 14.35                                       | <b>Improving HCV Treatment Uptake in Prison: Breaking the 60-Day Barrier</b><br>Zameer Mohamed, Imperial College London, United Kingdom  | 14.30 - 14.35        | <b>Use of Simplified HCV Testing, Diagnosis and Generic Sofosbuvir/Velpatasvir Treatment Leading to 100% SVR12 in Myanmar (USAID/EQUIP Project)</b><br>Yin Min Thauung, Community Partners International, Myanmar                           | 14.30 - 14.35 | <b>Accelerating the Hepatitis C Care Cascade for Patients with Substance Use</b><br>Jessica Rienstra, Lummi Tribal Health Center, United States  |
| 14.35 - 14.40                                       | <b>Improving Engagement with Healthcare in Hepatitis C: a Randomised Controlled Trial of a Peer Advocacy Intervention</b><br>Marie Francis, University College London, United Kingdom  | 14.35 - 14.40        | <b>“Lost to Follow up” Patients Have Equivalent Sustained Viral Response Rates to Patients Attending their Scheduled SVR12 Visit.</b><br>Alison Boyle, NHS Greater Glasgow and Clyde, United Kingdom  | 14.35 - 14.40 | <b>The Cascade of HCV Care Among People Who Inject Drugs in a Norwegian Low-Threshold Setting: Increasing Treatment Uptake</b><br>Håvard Midgard, Oslo University Hospital, Norway   |
| 14.40 - 14.45                                       | <b>Mobile Community-Based Liver Health Assessment in Underserved Populations: The Hepcare Project</b><br>Julian Surey, University College London, United Kingdom   | 14.40 - 14.45        | <b>Hepatitis C Treatment in People Who Inject Drugs on Medication Assisted Therapy Versus People Attending a Needle Exchange Program NCT03093415</b><br>Andrew Seaman, Oregon Health & Sciences University, United States                   | 14.40 - 14.45 | <b>Difficult Venous Access: Addressing this Barrier to Care in Hepatitis Treatment Clinics</b><br>Sinead Sheils, Institution, Australia  |
| 14.45 - 14.50                                       | <b>Reinfection Following HCV DAA Therapy Among People Who Inject Drugs on Opioid Agonist Therapy: the Prevail Study</b><br>Matthew Akiyama, Montefiore Medical Center  | 14.45 - 14.50        | <b>HCV Cure Rates Among People Who Inject Drugs not Receiving Medication Assisted Treatment in an American Indian/Alaskan Native Population</b><br>Whitney Essex, Cherokee Nation Health Services, United States                            | 14.45 - 14.50 | <b>Treatment of Hepatitis C in a Cohort of Former and Current Injecting Drug Users in Nairobi, Kenya</b><br>Dmytro Donchuk, Médecins Sans Frontières, Belgium  |
| 14.50 - 14.55                                       | <b>Universal On-Site HCV-RNA Screening is Warranted Among Active People Who Inject Drugs Who Attend Harm Reduction Centres in Catalonia, Spain (HepCdetect II Study)</b><br>Elisa Martró, Germans Trias I Pujol University Hospital And Research Institute (IGTP), Barcelona   | 14.50 - 14.55        | <b>Collocation of Buprenorphine with HCV Treatment to Improve Adherence and Reduce Harm in People Who Inject Drugs with HCV: Update from the ANCHOR Study</b><br>Sarah Kattakuzhy, University Of Maryland School Of Medicine, United States | 14.50 - 14.55 | <b>END hepC-NM: a Collaborative Approach Towards Hepatitis C Elimination in a Resource Scarce Environment</b><br>Kim Page, University of New Mexico, United States   |
| 14.55 - 15.00                                       | <b>Uptake of Treatment for Hepatitis C Infection in People Who Inject Drugs: the Link Study</b><br>Rob Bielen, Hasselt University, Belgium   | 14.55 - 15.00        | <b>HCV Cascade of Care at an Integrated Community Facility for People who Inject Drugs</b><br>Leith Morris, School Of Public Health, University Of Queensland, Australia  | 14.55 - 15.00 | <b>RECAP: an Interprofessional Comprehensive Community-based Care Clinic for the Management of Hepatitis C Positive and At-Risk Individuals in Saint John, New Brunswick, Canada</b><br>Sarah Gander, Horizon Health, Canada |
| <b>15.00 - 15.30 Coffee Break &amp; Poster Tour</b> |  |                      |   |               |  |
| <b>15.30 - 17.20</b>                                | <b>Session O: Harm Reduction and HCV Prevention</b><br>Room: Sala I<br>Chairs: Eberhard Schatz & Dagmar Hedrich  | <b>15.30 - 17.20</b> | <b>Session P: Challenges for enhancing HCV care among PWID in low and middle income countries (sponsored by IAS and MDM)</b><br>Room: Sala II<br>Chairs: Niklas Luhmann & Edo Agustian  |               | <b>Session Q: Diagnostics</b><br>Room: Sala XII + Sala XIII<br>Chairs: Tanya Applegate & Christian Ramers  |
| 15.30 - 15.50                                       | <b>Novel HCV Prevention Strategies for People Who Inject Drugs</b><br>Patrizia Carrieri, Aix Marseille Université, INSERM, France  | 15.30 - 15.50        | <b>Together in Harm Reduction: Synergizing Efforts Between HIV and Hepatitis Programmes</b><br>Sarah Hess, World Health Organisation, Switzerland   | 15.30 - 15.50 | <b>Enhancing Hepatitis C and HIV Testing Using Rapid Diagnostic Antibody Testing in Marginalized Populations</b><br>Amy Nunn, Brown University, United States  |
| 15.50 - 16.10                                       | <b>State of the Art on Drug Treatment</b><br>Julie Bruneau, Université de Montréal, Canada   | 15.50 - 16.10        | <b>Improving Access to Care for People Who Inject Drugs in Kenya: From Pilot Study to National Programme</b><br>Abigael Lukhwaro, Médecins du Monde, Kenya  | 15.50 - 16.10 | <b>Point-of-care Finger-stick Hepatitis C RNA Testing: Broadening Access to Testing in the Community</b><br>Tanya Applegate, The Kirby Institute, University of New South Wales Sydney, Australia                            |
| 16.10 - 16.50                                       | <b>Supervised Injecting Sites, Drug Consumption Rooms and Overdose Prevention: Where do we Stand in 2018?</b><br>Joan Colom, Public Health Agency of Catalonia, Spain<br>Gabi Becker, Geschäftsführerin der Integrativen Drogenhilfe Frankfurt, Germany<br>Ricardo Fuentes, City of Lisbon, Portugal<br>Adriana Curado, GAT, Portugal<br>Dirk Schäffer, Deutsche Aids Hilfe, Germany | 16.10 - 16.30        | <b>Successful Community-led Efforts to Enhance HCV Prevention, Testing and Linkage to Care Among People Who Inject Drugs in Low and Middle-income Countries</b><br>Edo Agustian, Asian Network of People who Use Drugs (ANPUD)/PKNI, Asia   | 16.10 - 16.20 | <b>Hepatitis C Testing from Dried Blood Spots: Simplifying Testing to Broaden Community-Based Screening</b><br>John Dillon, University of Dundee, Scotland   |
| 16.50 - 17.20                                       | <b>Questions &amp; Discussion</b>  | 16.30 - 16.50        | <b>The Cost of Diagnostics</b><br>Annette Gaudino, Treatment Action Group, United States  | 16.20 - 16.40 | <b>Enhancing Diagnostic Access in Low and Middle-income Countries</b><br>Emmanuel Fajardo, Médecins Sans Frontières, Spain   |
|   |  | 16.50 - 17.20        | <b>Questions &amp; Discussion</b>   | 16.40 - 17.00 | <b>Panel Discussion</b>  |
| <b>19:00 - 23:00 Symposium Dinner</b>               |  |                      |   |               |  |

|                      |  |
|----------------------|--|
| <b>Day 3</b>         | <b>HCV treatment and access</b>  |
| 09.00 - 09.45        | Breakfast Symposium: Exploring New Models of Care with Decentralised HCV RNA Testing<br>Room: Sala I + II  |
| <b>10.00 - 12.00</b> | <b>Session R: Management of HCV in People Who Inject Drugs</b><br>Room: Sala I + II<br>Chairs: Rui Tato Marinho and Lynn Taylor  |
| 10.00 - 10.20        | Direct-Acting Antiviral Therapy: Have we Reached Perfectovir for People Who Inject Drugs?<br>Brian Conway, Vancouver ID Centre, Canada   |
| 10.20 - 10.40        | Management of Advanced Liver Disease and Risk of HCC<br>Massimo Colombo, University of Milan, Italy  |
| 10.40 - 11.00        | Life Beyond SVR - It is not Just About SVR: the Clinical Benefits of Successful DAA Therapy Beyond Cure<br>Alessio Aghemo, Humanitas Research Hospital, Italy  |
| 11.00 - 11.20        | Life Beyond SVR - It is not Just About SVR: the Social Benefits of Successful DAA Therapy Beyond Cure<br>Carla Treloar, Centre for Social Research in Health, UNSW Sydney, Australia                 |
| 11.20 - 11.30        | Questions & Discussion   |
| 11.30 - 11.45        | Adherence to Sofosbuvir and Velpatasvir Among People with Chronic HCV Infection and Recent Injection Drug Use: the SIMPLIFY Study<br>Evan Cunningham, The Kirby Institute, Australia                 |
| 11.45 - 12.00        | Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs: a Systematic Review and Meta-Analysis<br>Behzad Hajarizadeh, University Of New South Wales, Australia |
| <b>12.00 - 12.45</b> | <b>Coffee Break &amp; Poster Tour</b>  |
| <b>12.00 - 12.45</b> | <b>Session S: We aren't Hard to Reach if You Know How</b><br>Room: Sala I + II<br>Chairs: Jude Byrne & Daniel Simões   |
| 12.00 - 12.05        | User Driven HCV Clinic on 4 Wheels<br>Ole Jørgen Lygren, Prolamett, Norway   |
| 12.05 - 12.10        | Furthering the Hepatitis C Diagnosis Process to Easy Access and Comprehensive Coverage.<br>Janjira Lintong, TTAG, Thailand   |
| 12.10 - 12.15        | Models of Care - From Patient to Organizer of Community Testing<br>Anja Plener Bloch, Brugernes Akademy, Denmark   |
| 12.15 - 12.20        | Meaningful Involvement of Indonesian Drugs User Network in Respond and Availability HCV treatment Access in Indonesia<br>Andika Wibaskara, Indonesian Drugs User Network, (PKNI), Indonesia          |
| 12.20 - 12.45        | Panel Discussion   |
| <b>12.45 - 13.45</b> | <b>Lunch</b>   |
| 13.00 - 13.45        | INHSU GAM  |

|                                   |   |               |  |               |  |
|-----------------------------------|---|---------------|--|---------------|--|
| 13.45 - 14.45                     | <b>Session T: HCV Reinfection</b><br>Room: Sala XII + XIII<br>Chairs: Stefan Christensen & Sarah Kattakuzhy   | 13.45 - 14.45 | <b>Session U: It is Not Always Just About HCV: Drug User Health and HCV</b><br>Room: Sala I<br>Chairs: Kathryn Leafe & Suzanne Brissette   | 13.45 - 14.45 | <b>Session V: Models of Care for HCV Infection</b><br>Room: Sala II<br>Chairs: Monica Sousa & Martin Kåberg  |
| 13.45 - 14.00                     | <b>High Re-Infection Rates Among People Who Inject Drugs Successfully Treated for Hepatitis C in a Community Needle and Syringe Programme</b><br>Jasmine Schulkind, University Bristol, United Kingdom  | 13.45 - 14.00 | <b>Care Beyond the Virus: Engaging the Most Marginalised in Hepatitis C Care</b><br>Magdalena Harris, London School Of Hygiene & Tropical Medicine, United Kingdom   | 13.45 - 14.00 | <b>Experience and Outcomes of a High Volume Homeless Health Center-Based HCV Treatment Program in Boston</b><br>Marguerite Beiser, Boston Health Care For The Homeless, United States  |
| 14.00 - 14.15                     | <b>Reinfection and Retreatment: Attitudes Among Prisoner Participants from the Australian STOp-C Study</b><br>Jake Rance, Centre For Social Research In Health, Australia   | 14.00 - 14.15 | <b>Sex, Drugs and HCV: The Role of Sex and Sex Work in Hepatitis C Virus Infection Among People who Inject Drugs in Montréal</b><br>Brendan Jacka, CHUM Research Centre, Canada  | 14.00 - 14.15 | <b>Treating People Where They Are: Lessons from Outreach HCV Treatment for Networks of People With Recent Injecting Drug Use in Victoria, Canada</b><br>Tamara Barnett, Cool Aid Community Health Centre, Canada   |
| 14.15 - 14.30                     | <b>Reinfection Following Successful HCV DAA Therapy Among People with Recent Injecting Drug Use: The SIMPLIFY and D3FEAT Studies</b><br>Evan Cunningham, The Kirby Institute, University of New South Wales, Australia  | 14.15 - 14.30 | <b>Preliminary Analysis of the Prime Study; a Randomized Controlled Trial Comparing the Hepatitis C Care Cascade in Primary Care Vs. Tertiary Care</b><br>Margaret Hellard, Burnet Institute, Australia  | 14.15 - 14.30 | <b>Building Bridges to Eliminate HCV in People Who Inject Drugs: Knowledge and Planned Performance Change Among HCV Treators and Addiction-services Providers Engaged in a Pilot Education Initiative</b><br>Jody Gilmore, Penn Presbyterian Medical Center, United States |
| 14.30 - 14.35                     | <b>Drug Use and Reinfection During and Following Hepatitis C Virus (HCV) Treatment With Elbasvir/Grazoprevir (EBR/GZR) Among Patients Receiving Opioid Agonist Therapy (OAT): the C-Edge Co-Star Study</b><br>Gregory Dore, Kirby Institute, University of New South Wales, Australia | 14.30 - 14.35 | <b>Changes in Drug and Alcohol Use and Injection Risk Behaviours Among People Who Inject Drugs During and Following HCV Direct-Acting Antiviral Treatment: the SIMPLIFY and D3FEAT Studies</b><br>Andreea Adelina Artenie, Université de Montréal, Canada                      | 14.30 - 14.35 | <b>Liberating Medeco-Inala from Hep C. a Study of Micro-Elimination in Primary Care</b><br>Matthew Young, Medeco-Inala, Australia  |
| 14.35 - 14.40                     | <b>Low HCV Reinfection Rate After Treatment in People Who Inject Drugs (PWID) from a Prospective Cohort in Tbilisi, Georgia</b><br>Tamar Kikvidze, Médecins Du Monde, France  | 14.35 - 14.40 | <b>Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results from the German Hepatitis C-Registry</b><br>Eric Crown, AbbVie, United States | 14.35 - 14.40 | <b>Chronic Hepatitis C Eradication Model Through Primary Care in British Columbia, Canada</b><br>John Farley, Dr. John Farley Inc., Canada   |
| 14.40 - 14.45                     | <b>Low Rate of Reinfection Following Direct-Acting Antiviral HCV Treatment Among People with Recent Injecting Drug Use: a Real-Life Experience</b><br>Håvard Midgard, Oslo University Hospital, Norway  | 14.40 - 14.45 | <b>Treatment Outcomes Achieved With All-Oral Hepatitis C Treatment in People Who Currently Inject Drugs: a Systematic Review and Meta-Analysis</b><br>Ned Latham, Burnet Institute, Australia  | 14.40 - 14.45 | <b>Hepatitis C Care in an Opioid Substitution Treatment Unit</b><br>Simon Larsson, Sahlgrenska University Hospital, Sweden   |
| <b>14.45 - 15.15 Coffee Break</b> |   |               |  |               |  |
| 15.15 - 16.30                     | <b>Session X: Enhancing access to HCV care for PWID</b><br>Room: Sala XII + XIII<br>Chairs: Américo Nave & Maqda Ferreira   | 15.15 - 16.30 | <b>Session Y: Enhancing HCV prevention and treatment in prisons</b><br>Room: Sala I + II<br>Chairs: Nadine Kronfli & Andrew Lloyd  |               |  |
| 15.15 - 15.35                     | <b>Advocacy for affordable access to DAA therapy from the community perspective: Lessons from Malaysia</b><br>Yatie Jonet, Malaysian AIDS Council, Malaysia   | 15.15 - 15.35 | <b>Needle and Syringe Programmes for HCV Prevention in Prisons: Where do we Stand Globally?</b><br>Rick Lines, Hilary Rodham Clinton School of Law, Swansea University, United Kingdom   |               |  |
| 15.35 - 15.55                     | <b>Working Towards Addressing Stigma</b><br>Erin O'Mara, European Network of People who Use Drugs, United Kingdom   | 15.35 - 15.55 | <b>Enhancing Access to HCV Testing and Treatment in Prisons: Lessons Learned from Australia</b><br>Alex Thompson, University of Melbourne, Australia   |               |  |
| 15.55 - 16.15                     | <b>Enhancing Access to HCV Testing and Treatment Among People Who Use Drugs: Lessons from Brazil</b><br>Francisco Inácio Bastos, Oswaldo Cruz Foundation, Brazil  | 15.55 - 16.15 | <b>Enhancing Access to HCV Testing and Treatment in Prisons: Lessons Learned from Spain</b><br>Joan Colom, Public Health Agency of Catalonia, Autonomous Government of Catalonia, Spain  |               |  |
| 16.15 - 16.30                     | <b>Questions &amp; Discussion</b>   | 16.15 - 16.30 | <b>Questions &amp; Discussion</b>  |               |  |
| 16.30 - 17.10                     | <b>Session Z: Reports and Symposium Closing</b><br>Room: Sala I + II<br>Chairs: Ricardo Baptiste Leite and Julie Bruneau  |               |  |               |  |
| 16.30 - 16.40                     | <b>Policy &amp; Epidemiology Rapporteur</b><br>Natasha Martin, University of California, United States  |               |  |               |  |
| 16.40 - 16.50                     | <b>Linkage to Care &amp; Treatment Rapporteur</b><br>Alisa Pedrana, Burnet Institute, Australia   |               |  |               |  |
| 16.50 - 17.00                     | <b>Models of Care Rapporteur</b><br>Anne Øvrehus, Rigshospitalet, Denmark   |               |  |               |  |
| 17.00 - 17.10                     | <b>Community Rapporteur</b><br>Annie Madden, Centre for Social Research in Health, University of New South Wales, Australia   |               |  |               |  |
| 17.10 - 17.15                     | <b>Symposium Closing and Introduction of Upcoming Conference</b>  |               |  |               |  |